Gender Male
LinkedIn View on LinkedIn
David McGibney is clinical and drug development advisor to Imperial Innovations Ltd. He previously held senior R&D positions at Pfizer, including SVP and Head of European R&D 1998-2001 and VP and Head of European Clinical Research and Regulatory Affairs 1992-1998. During his tenure at Pfizer, David was instrumental in the successful
development and registration of numerous medicines, including Amlodipine (Norvasc™), Doxazosin (Cardura™), Fluconazole (Diflucan™), Sertraline (Zoloft™), Sildenafil (Viagra™), Dofetilde (Tikosyn™), Eletriptan (Relpax™), Voriconazole (VFend™), Trovafloxacin (Trovan™), Ziprasidone (Geodon™), Darifenacin (Enablex™), Azithromycin (Zithromax™), and Donepezil (Aricept™). From 2002-2004, David was Executive Director and Head of Drug Discovery and Development at Avidex Ltd.
As a consultant to the pharmaceutical industry, he works closely with biotechnology companies, lifescience investors, and non-profit healthcare organizations, including Heptares Therapeutics Ltd (CMO and Head of Development), Medicines for Malaria Venture (Chairman of Expert Scientific Advisory Committee and Member of Global Safety Board), Convergence Ltd (Board observer), Vantia Ltd (Chairman of Development Subcommittee), Kalvista Ltd (Chairman of Advisory Committee).
He is a clinical and product development advisor to Nanoform Therapeutics, Isis Pharmaceuticals Inc., as well as to venture investors Apposite Capital, Abingworth, MVM Life Science Partners, and Radius Ventures. David previously served as Board Director at Isogenica Ltd and Fovea Pharmaceuticals SA, chaired the Development Teams at Athersys Inc and Cellzome Ltd, and was an advisor to Excaliard Inc.
